FDA Releases Regulatory Science Priorities for Medical Devices in 2017

September 30, 2016

FDA Center for Devices and Radiological Health (CDRH) Regulatory Science Priorities 2017

On Thursday, September 22nd, the FDA’s Center for Devices and Radiological Health (CDRH) released its regulatory science priorities for fiscal year 2017.

CDRH & Regulatory Science

According to CDRH, regulatory science is aligned with and supports both its mission and vision.  In addition, the Center states that it feels regulatory science “must be proactive and anticipate regulatory and public health issues, while also being responsive to emergent issues.”

The Center’s “regulatory science priorities serve as a catalyst to improving the safety, effectiveness, performance and quality of medical devices and radiation-emitting products and to facilitate introducing innovative medical devices into the marketplace.”  These priorities are identified on an annual basis and are reassessed and updated periodically to reflect the current needs.  Furthermore, CDRH states that its regulatory science priorities are intended to serve as a guide for making strategic decisions regarding intramural research funding.  This helps to “ensure that CDRH research is focused on needs that are relevant and critical to medical devices and radiation-emitting products.”

Determining the Regulatory Science Priorities for 2017

Using the feedback provided from CDRH staff and senior leadership, the 2017 priorities were identified by the Regulatory Science Subcommittee (RSS) under the direction of the Center Director and the RSS co-chairs.  CDRH states that it used the following approach in developing its priorities:

  • “Regulatory science needs collected in FY2015 were combined with the ones we identified in FY2016.
  • Regulatory science needs were clustered according to their affinity.
  • The individual needs and their general categories were scored using a set of criteria described below.
  • The proposed top ten priorities were reviewed and approved by our senior leadership and Center Director to ensure alignment with our Center’s and Agency’s priorities.”

In addition, the Center also notes that the “regulatory science needs were assessed for their regulatory and public health impact using the following criteria:

  • Will addressing the need facilitate medical device innovation and bring new technology to market?
  • Will addressing the need enhance or expedite the availability of medical devices and radiation-emitting products while maintaining their safety and effectiveness?
  • Will addressing the need facilitate rapid identification of problems, improve our postmarket understanding of the benefit-risk profile of devices or radiation-emitting products and aid future premarket device clearance or approval?
  • What is the public health impact of the need?”

2017 Regulatory Science Priorities

The following are CDRH’s 2017 regulatory science priorities:

  1. Leverage “Big Data” for regulatory decision-making
  2. “Modernize biocompatibility and biological risk evaluation of device materials
  3. Leverage real-world evidence and employ evidence synthesis across multiple domains in regulatory decision-making
  4. Advance tests and methods for predicting and monitoring medical device clinical performance
  5. Develop methods and tools to improve and streamline clinical trial design
  6. Develop computational modeling technologies to support regulatory decision-making
  7. Enhance the performance of Digital Health and medical device cybersecurity
  8. Reduce healthcare associated infections by better understanding the effectiveness of antimicrobials, sterilization and reprocessing of medical devices
  9. Collect and use patient input in regulatory decision making
  10. Leverage precision medicine and biomarkers for predicting medical device performance, disease diagnosis, and progression
Do you manufacture a medical device or other FDA-regulated product? We can help you achieve a successful interaction with FDA.  To learn more about our services and how we can help you, contact us today.

Life Science Consulting Pre-Approval Inspection

June 23, 2020

6 Tips for Evaluating Your CMO’s PAI Readiness

The submission of your drug application (NDA, ANDA, BLA, etc.) is an exciting accomplishment, and one of the first major milestones is a pre-approval inspection (PAI) of the manufacturing sites...

Read the Full Article
Regulatory Sciences

June 1, 2021

Best Practices to Reduce Impurities in Generics

Recent recalls of dozens of lots of the front-line blood pressure and heart medications including valsartan, losartan, and irbesartan are placing the spotlight on impurities in generic drugs. After...

Read the Full Article
Regulatory Sciences

February 18, 2021

Brexit: New Regulatory Opportunities in the United Kingdom

As the dust settles on the final Brexit deal, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is forging new opportunities to innovate, increasing its efficiency, and...

Read the Full Article